Dish of the day

Joiners: 

No joiners today. 

Leavers: 

Curtis Banks Groups Plc (CBP.L) has left AIM . 

 

What’s cooking in the IPO kitchen?** 

Kitchen is empty currently.

 

Banquet Buffet*** 

Biome Technologies 160p  £6.1m (BIOM.L) 

The bioplastics and radio frequency technology business announces its unaudited interim results for the six months ended 30 June 2023. The Group announced revenues of £3.6m (2022 H1: £2.4m), up 47% and as a result gross profit increased to £1.1m (2022 H1: £0.9m). Total comprehensive loss was £1.1m (2022 H1: £0.6m loss). Cash position as at 30 June 2023 was £0.9m, reflecting H1 2023 trading, working capital movements, £0.85m proceeds from the convertible loan notes repayable in 2026. The Group's trading in 2023 is broadly in-line with current market expectations.  

 

Longboat Energy 16.75p  £9.5m (LBE.L) 

The emerging full-cycle E&P company, announces its unaudited interim results for the period to 30 June 2023. Post-tax loss for the period was £6.2m (30 June 2022: £1.6m). Gross cash at 30 June 2023 was £2.1m (30 June 2022: £22.5m ), which excludes cash of £2.2m in Longboat Energy Norge AS. The Company has formed a joint venture in Norway with Japan Petroleum Exploration Co, Ltd (JAPEX). JAPEX made a investment with an initial $16m subscription, with a further $4m contingent payment, and providing a $100m financing facility. The Company has also entered into an agreement through the new Norwegian joint venture to acquire its first producing assets in Norway. 

 

MTI Wireless Edge 45p  £39.8m (MWE.L) 

The technology group focused on comprehensive communication and radio frequency solutions across multiple sectors, announces that its Antenna division has received orders from the Indian divisions of two large Original Equipment Manufacturers worth approximately US$0.6m for its 5G backhaul antenna solution. It is expected to be delivered by the end of this year and the orders have been placed by existing customers. 

 

OptiBiotix Health 24.75p  £22.6m (OPTI.L) 

The life sciences business developing compounds to tackle obesity, cardiovascular disease, diabetes and skincare, announces its unaudited results for the six months ended 30 June 2023. Sales were £351k (2022: £119k), up 195% year-on-year and as a result, gross profit increased 154% to £158k (2022: £62k). Three new partners in Asia have all placed initial orders for SlimBiome® with a large first order from a new partner of £116k. The Company announced on 29 August 2023, one of their partners has secured an international listing for products containing SlimBiome® with Costco and have reached an agreement with Boots pharmacies to launch SlimBiome® products online in Q1 2024. 

 

Plant Health Care 7.33p  £25.0m (PHC.L) 

The provider of biological products to global agriculture markets, announces its unaudited interim results for the six months ended 30 June 2023 (H1 2023). Revenue increased by 1% to $5.6m (H1 2022: $5.5m), gross profit materially decreased to $3.38m (H1 2022: $3.4m) and operating loss reduced to $2.5m (H1 2022: $6.2m). Cash used in operations increased 33% to $2.8m H1 2022: $2.1m). Cash as at 30 June 2023 was $5.7m, after Group raised $3.3m net proceeds during the period. A new PREtec product for the control of soil nematodes received the first regulatory approvals for commercial use in Brazil and the Company is on track to achieve revenue of $30m by 2025. 

 

Roquefort Therapeutics* 7.5p  £9.7m (ROQ.L) 

The biotech company focused on developing first-in-class medicines in the high value and high growth oncology market, announces its interim results for the six-month period ended 30 June 2023. Revenue from licencing was £200k. Net loss was £742k and cash position at period end was £1.4m. During the period, the Company signed exclusive worldwide license agreement (excluding Japan) with Randox Laboratories for 10 years to utilise Midkine antibodies in diagnostics. Key milestones were achieved with ROQ-A1 and ROQ-A2 Midkine antibody programs, targeting metastatic breast cancer, and lung and liver metastasis which have successfully demonstrated in vivo safety. The Company is on course for clinical readiness for one of its development programs during H2 2023.  There are also near-term IND and licensing opportunities from advanced stage of development of Midkine portfolio products, MK cell and siRNA products.  

 

Safestyle UK 4.69p  £6.5m (SFE.L) 

The UK-focused retailer and manufacturer of PVCu replacement windows and doors for the homeowner market, announces its interim results for the six months ended 2 July 2023 (H1). Revenue decreased by 5.3% to £74.1m, (H1 2022: £78.3m), as a result gross profit decreased 16.1% to £16.2m (H1 2022: £19.4m). Underlying loss before tax increased by 323% to £6m (H1 2022: £1.4m in losses) . The Company held a net cash of £1.0m at the period end. The Board maintains growth recovery prospects and highlights the progress described in the Group's strategic priorities, its transformation and market share growth as signs that there remains a compelling opportunity to achieve its medium-term target. 

 

Saietta Group 40p  £41.2m (SED.L) 

The multi-national business which designs, engineers and manufactures complete electric drivetrain (eDrive) solutions for electric vehicles, announces that its Indian joint venture, Saietta VNA, has received a purchase order for supply of complete eDrives. The customer is a global OEM and the purchase order covers approximately £420k of systems for the first three months of production. However, target volumes indicated by the client for the first year of production is expected to generate revenue for Saietta VNA in excess of £11.2m. It is expected to build to a minimum of 40,000 complete systems over a five-year period.  

 

Simec Atlantis Energy 1.08p  £7.8m (SAE.L) 

The company focusing on the creation of new, sustainable energy projects, announces its unaudited interim results for the six months ended 30 June 2023. Profit before tax was £4.5m (compared to a loss of £8.6m in 1H 2022), thanks to £10m development premium received from Uskmouth Energy Storage Ltd as revenue. The Company’s cash position as at 30 June 2023 was £1.5m and financial costs in the period are materially in line with the same period last year. The MeyGen Phase 1 array continues to operate successfully, with three turbines in stable operations whilst the fourth is currently undergoing preventative maintenance and upgrade works and will return to operation next year. 

 

Zinc Media Group 102.5p  £22.7m (ZIN.L) 

The television, brand and audio production group, announces its unaudited interim results for the six months to 30 June 2023 (H1 2023). Revenue was £18.1m (H1 2022: £10.8m), an increase of 68% year-on-year, as a result adjusted EBITDA profit of £0.2m compared to an Adjusted EBITDA profit of £0.1m in the entire prior financial year (H1 2022: loss of £0.6m). Cash balance was £5.8m at 30 June 2023. With a further £7m of revenue expected to be recognised in FY23, the Board is confident in meeting market expectations for the financial year. 

 

* A corporate client of Hybridan LLP

** Arranged by most recent first

*** Alphabetically arranged

 

Status of this Note and Disclaimer

This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.

Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of the UK retained version of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in the UK retained version of article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II       Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).

This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii)  persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.

Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.